Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: Protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)-4-oxobut-2-enoate- sodium (PD 155080)

Journal of Pharmacology and Experimental Therapeutics

Volumn 300, Issue 2, 2002, Pages 442-449

  Brunner, Friedrich ^a   WöLkart, Gerald ^a   Haleen, Stephen ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; CALCIUM; ENDOTHELIN A RECEPTOR; MONOCROTALINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CALCIUM CELL LEVEL; CALCIUM METABOLISM; CALCIUM TRANSPORT; CONTROLLED STUDY; FEMALE; HEART FUNCTION; HEART PROTECTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE;

AEQUORIN; ANIMALS; CALCIUM; CALCIUM SIGNALING; DIOXOLES; ENDOTHELIN-1; FEMALE; HEMODYNAMIC PROCESSES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUMINESCENT MEASUREMENTS; MONOCROTALINE; MYOCARDIAL CONTRACTION; PERFUSION; POISONS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; VENTRICULAR FUNCTION, RIGHT;

EID: 0036154426     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.300.2.442     Document Type: Article

References (36)

1. Alterations in calcium handling in cardiac hypertrophy and heart failure
2. 2+ measurements
3. Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats
4. Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat
5. Cardiac endothelin and big endothelin in right-heart hypertrophy due to monocrotaline-induced pulmonary hypertension in rat
6. Endothelin receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
7. Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists
8. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats
9. Endothelin-1 is elevated in monocrotaline pulmonary hypertension
10. Comparison of twitch force and calcium handling in papillary muscles from right ventricular pressure overload hypertrophy in weanling and juvenile ferrets
11. Altered calcium handling in experimental pressure-overload hypertrophy in the ferret
12. Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension
13. Telemetry monitoring of pulmonary arterial pressure in freely moving rats
14. Nonspecific endothelinreceptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats
15. Signaling hypertrophy: How many switches, how many wires
16. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium
17. Endothelins and cardiac hypertrophy
18. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats
19. Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart
20. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling
21. B receptors, and ECE and distribution of endothelin-1 in failing rat heart
22. Changing patterns of gene expression in the pulmonary trunk-banded rat heart
23. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats
24. Pathophysiology of cardiac hypertrophy and failure of human working myocardium: Abnormalities in calcium handling
25. Elastic properties of the myocardium: A quantitative approach with physiological and clinical applications
26. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension
27. Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats
28. The orally active ETA receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3-3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats
29. Role for endothelin-1 in angiotensin II-mediated hypertension
30. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
31. Enhanced expression of endothelin-1 gene may cause blood pressure-independent vascular hypertrophy
32. Validation of different methods to compare cardiac function in isolated hearts of varying sizes
33. 2+ ATPase promoter activity during endothelin-1 induced hypertrophy of cultured rat cardiomyocytes
34. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
35. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
36. Calcium handling and role of endothelin-1 in monocrotaline right ventricular hypertrophy of the rat